trastuzumab + docetaxel + NPLD + bevacizumab

This is a combination regimen consisting of four drugs: trastuzumab, docetaxel, nonpegylated liposomal doxorubicin (NPLD), and bevacizumab. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), used primarily in HER2-positive breast cancer. Docetaxel is a taxane-class small molecule chemotherapeutic that inhibits microtubule depolymerization, disrupting cell division. NPLD (nonpegylated liposomal doxorubicin) is an anthracycline antibiotic encapsulated in liposomes to reduce cardiotoxicity while intercalating DNA and inhibiting topoisomerase II. Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This combination has been studied for efficacy and safety in HER2-positive metastatic or early-stage breast cancer, with particular attention to cardiac toxicity due to the inclusion of both anthracyclines and anti-HER2 therapy[1][4][6].

Brand names

Caelyx

Other names

pegylated liposomal doxorubicin